Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Home › Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Tamp down your hopes and dreams if you were expecting Achillion to be the next hepatitis C buyout candidate. Achillion shares are up 18% to $16.84.

05.11	Boeing strike ends as workers back 38% pay rise deal
05.11	Tropical Storm Rafael Public Advisory Number 6A
05.11	Summary for Tropical Storm Rafael (AT3/AL182024)
05.11	Tropical Storm Rafael Graphics
05.11	Atlantic Tropical Weather Outlook
05.11	Eastern North Pacific Tropical Weather Outlook
05.11	Tropical Storm Rafael Graphics
05.11	Tropical Storm Rafael Forecast Discussion Number 6
More »

je.st